Figure 4. Levetiracetam blocks Kv4.2 depletion in hAPPJ20 mice. A, hAPPJ20 mice showed increased ambulatory distance in open field when pretested before LEV treatment (age 4–5 months, p < 0.0001, t test). B, After 18 d of LEV treatment, hAPPJ20 mice showed normal ambulatory distance (ANOVA: hAPP × treatment interaction, p < 0.05, **p < 0.01 on post hoc test). C, Representative images of calbindin immunohistochemistry after 28 d of LEV treatment. D, Quantification of calbindin immunoreactivity after 28 d of LEV treatment, expressed as the ratio of DG to CA1 immunoreactivity as in Palop et al. (2011). hAPPJ20 mice treated with LEV showed normal levels of calbindin (ANOVA: hAPP × treatment interaction, p < 0.05, **p < 0.01 on post hoc test; age 5–6 months). E, Quantification of Kv4.2 after LEV treatment for 28 d. LEV blocked the Kv4.2 depletion in the hAPPJ20 mice. Representative blots and quantification of Kv4.2 in the DG of hAPPJ20 mice (ANOVA: hAPP effect, p < 0.05, **p < 0.01 on post hoc test; age 5–6 months).